andrea ferrante: assessment of mhc class ii-restricted epitope prediction in silico
Published 4 years ago • 495 plays • Length 38:19Download video MP4
Download video MP3
Similar videos
-
51:29
andrea ferrante: in-silico prediction of immunogenicity: filling the gaps
-
6:41
prot2® mhc class ii tetramers
-
19:59
edmund neo: epitope identification and clinical immune monitoring tools
-
17:10
edmund neo: epitope identification and clinical immune monitoring tools
-
33:11
tim hickling: application of immunogenicity prediction and mitigation for biotherapeutic development
-
45:14
jeremy fry: tools and technologies for comprehensive immunogenicity risk management
-
3:26
eofy- myob acumatica – fixed assets
-
1:14:24
"assessment of anomia: improving efficiency and utility", gerasimos fergadiotis
-
1:03:20
the immune epitope database
-
36:05
vibha jawa: risk assessments to drive clinical immunogenicity strategy
-
27:48
tim elliot: applying mechanism based computational models to ctl epitope prediction
-
36:50
tim hickling: contribution of ex vivo assays to immunogenicity risk assessment
-
28:50
jeremy fry: an integrated approach to managing immunogenicity risk and drug immune modulation
-
26:49
stephen man: cd8 t cell recognition of unusual and unnatural peptide epitopes
-
25:47
heather hinton: pre clinical risk assessment technologies
-
32:21
jeremy fry: an integrated approach to managing immunogenicity risk and drug immune modulation
-
31:11
jeremy fry: an integrated approach to managing immunogenicity risk and optimum protein design
-
14:24
the finance of immunogenicity
-
51:40
valerie quarmby: assessing immunogenicity risk in biotherapeutic development